CLINICAL_TRIALS
trial_result
· 2021-02-18
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus [Phase 2]
Summary
Phase 2 trial evaluating CC-220 (iberdom, pomalidomide analog) for efficacy and safety in active systemic lupus erythematosus completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2021-02-18